Merck unveils positive results from clinical trial of KEYTRUDA for breast cancer
KEYTRUDA is a humanised monoclonal antibody designed to block the interaction between PD-1 to activate the T lymphocytes
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 May 20
KEYTRUDA is a humanised monoclonal antibody designed to block the interaction between PD-1 to activate the T lymphocytes
13 May 20
Moderna designed the new mRNA-1273 is an mRNA vaccine to work against SARS-CoV-2 encoding for a prefusion stabilised…
12 May 20
Lynparza is an advanced PARP inhibitor and the targeted treatment to block DNA damage response (DDR) in cells…
11 May 20
The FDA indicated Retevmo for treating a type of RET fusion-positive NSCLC, RET-mutant MTC, RET fusion-positive thyroid cancer…
11 May 20
With the regulatory approval, Entyvio becomes the only maintenance therapy for Crohn’s disease, with both intravenous and subcutaneous…
08 May 20
The regulatory approval is based on data from the US National Institute of Allergy and Infectious Diseases’ Phase…
07 May 20
The company said that ELYXYB is the latest product from its portfolio of acute migraine treatments, and is…
07 May 20
Tabrecta demonstrated 68% overall response rate in treatment-naive patients and 41% in previously treated METex14 patients
06 May 20
Farxiga is a sodium-glucose co-transporter 2 (SGLT2) inhibitor intended to treat heart failure with reduced ejection fraction in…
04 May 20
The FD authorisation will enable the use of remdesivir to treat hospitalised patients with severe Covid-19 disease in…